Plymouth, Mass. – Beth Israel Deaconess Hospital–Plymouth (BID Plymouth) received an “A” Hospital Safety Grade from The Leapfrog Group for the 15th consecutive measurement period. This national distinction celebrates BID Plymouth’s achievements in protecting hospital patients from preventable harm and errors.
"Providing exceptional care is, undoubtedly, the top priority for each and every one of our clinicians, nurses and caregivers," said Kevin Coughlin, president of Beth Israel Deaconess Hospital–Plymouth. "We are so proud to receive this 'A' grade for the fifteenth time in a row, and we will continue to provide the safest environment possible for our patients. We thank the Leapfrog Group for this award."
The Leapfrog Group is an independent national watchdog organization with a 10-year history of assigning letter grades to general hospitals throughout the United States, based on a hospital’s ability to prevent medical errors and harm to patients. The grading system is peer-reviewed, fully transparent, and free to the public. Hospital Safety Grade results are based on more than 30 national performance measures and are updated each fall and spring.
"I applaud the hospital leadership and workforce for their strong commitment to safety and transparency," said Leah Binder, president and CEO of The Leapfrog Group. "An 'A' Safety Grade is a sign that hospitals are continuously evaluating their performance, so that they can best protect patients. Your hospital team should be extremely proud of their dedication and achievement."
To see BID Plymouth's full grade details and to access patient tips for staying safe in the hospital, visit HospitalSafetyGrade.org and follow The Leapfrog Group on Twitter, Facebook, and via its newsletter.
About Beth Israel Deaconess Hospital–Plymouth
Beth Israel Deaconess Hospital–Plymouth is a non-profit healthcare and hospice provider, serving 250,000 residents of 12 towns in Plymouth and Barnstable Counties. BID Plymouth is a full-service, 170-bed acute care community hospital accredited by The Joint Commission, the College of American Pathologists, the American College of Surgeons Commission on Cancer, and the American College of Radiology.